Key facts
- Chinese biotechnology companies have set new records for out-licensing agreements.
- The increase in these deals coincides with growing scrutiny from the United States.
- This trend highlights the complex geopolitical and regulatory environment for Chinese biotech innovation.
Chinese biotechnology companies are experiencing an unprecedented wave of out-licensing deals, marking a new record for the sector. This surge in international partnerships and technology transfers occurs at a time when the United States is intensifying its scrutiny of such activities. The growing attention from US authorities could signal potential challenges for the continued expansion and global integration of China's biotech industry, raising questions about future trade relations and regulatory compliance.